The genetics of the amyloidoses

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 543-569

  Buxbaum, Joel N ^a   Tagoe, Clement E ^b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloidosis; Familial Mediterranean fever; Serum amyloid A; Transthyretin

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PREALBUMIN; PRESENILIN 1; PRESENILIN 2; SERUM AMYLOID A;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYLOIDOSIS; ARTHROPATHY; AUTOSOMAL DOMINANT INHERITANCE; CARDIOMYOPATHY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; NONHUMAN; ONSET AGE; PRION DISEASE; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEINS A; HUMANS;

EID: 0034088778     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.543     Document Type: Review

References (138)

1. 1. Chiti F, Webster P, Taddei N, et al. 1999. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96:3590-94
2. 2. Episkopou V, Maeda S, Nishiguchi S, et al. 1993. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc. Natl. Acad. Sci. USA 90:2375-79
3. 3. Kanda Y, Goodman DS, Canfield RE, Morgan FJ. 1974. The amino acid sequence of human plasma prealbumin. J. Biol. Chem. 249:6796-805
4. 4. Blake CCF, Geisow MJ, Oatley SJ. 1978. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8A. J. Mol. Biol. 121:339-56
5. 5. Monaco HL, Rizzi M, Coda A. 1995. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268:1039-41
6. 6. Whitehead AS, Skinner M, Bruns GAP, et al. 1984. Cloning of human prealbumin complementary DNA. Localization of the gene to chromosome 18 and detection of a variant prealbumin allele in a family with familial amyloid polyneuropathy. Mol. Biol. Med. 2:411-23
7. 7. Wallace MR, Naylor SL, Kluve-Beckerman B, et al. 1985. Localization of the human prealbumin gene to chromosome 18. Biochem. Biophys. Res. Commun. 129:753-58
8. 8. Andrade C. 1952. A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408-27
9. 9. Andersson R. 1976. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med. Scand. Suppl. 590:1-64
10. 10. Sakoda S, Suzuki T, Higa S, et al. 1983. Genetic studies of familial amyloid polyneuropathy in the Arao district of Japan: 1. The genealogical survey. Clin. Genet. 24:334-38
11. 11. Benson MD, Cohen AS. 1977. Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann. Intern. Med. 86:419-24
12. 12. Saraiva MJM, Birken S, Costa PP, Goodman DS. 1984. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest. 74:104-19
13. 13. Tawara S, Nakazato M, Kangawa K, et al. 1983. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem. Biophys. Res. Commun. 116:880-88
14. 14. Dwulet FE, Benson MD. 1984. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc. Natl. Acad. Sci. USA 81:694-98
15. 15. Jacobson DR, Santiago-Schwarz F, Buxbaum JN. 1988. Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familial amyloidotic polyneuropathy. Biochem. Biophys. Res. Commun. 153:198-202
16. 16. Wallace MR, Dwulet FE, Williams EC, et al. 1988. Identification of a new hereditary amyloidosis prealbumin variant, Tyr-77, and detection of the gene by DNA analysis. J. Clin. Invest. 81:189-93
17. 17. Nichols WC, Liepnieks JJ, McKusick VA, Benson MD. 1989. Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II genotyping by allele specific enzymatic amplification. Genomics 5: 535-540
18. 18. 1999. Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Int. Workshop Liver Transplant. Fam. Amyloid Polyneuropathy, 3rd, June 3-5, Umeå Sweden
19. 19. Jacobson DR, Alves IL, Saraiva MJ, et al. 1995. Transthyretin Ser 6 gene frequency in individuals without amyloidosis. Hum. Genet. 95:308-12
20. 20. Kelly JW, Lansbury PT Jr. 1994. A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation. Amyloid: Int. J. Exp. Clin. Invest. 1:186-205
21. 21. Thylen C, Wahlqvist J, Haettner E, et al. 1993. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J. 12:743-48
22. 22. McCutchen SL, Kelly J. 1993. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro. Biochem. Biophys. Res. Commun. 197:415-21
23. 23. McCutchen SL, Lai Z, Miroy GJ, et al. 1995. Comparison of lethal and nonlethal transthyretin variants and their relationship to disease. Biochemistry 34:13527-36
24. 24. Coelho T, Sousa A, Lourenco E, Ramalheira J. 1994. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J. Med. Genet. 31:293-99
25. 25. Sousa A, Coelho T, Lobato L, Sequeiros J. 1999. Anticipation of age-at-onset in Portuguese patients with familial amyloid polyneuropathy-type I (FAP-Met30). In Amyloidosis, ed. MA Gertz, RA Kyle. New York/London: Parthenon. In press
26. 26. Soares M, Buxbaum J, Sousa A, et al. 1999. Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Hum. Genet. 104:480-85
27. 27. Sousa A, Coelho T, Sequeiros J. 1990. Parental transmission and age-of-onset in familial amyloidotic polyneuropathy (Portuguese type). In Amyloid and Amyloidosis, ed. JB Navtig, Ø Førre, G Husby, et al, pp. 691-93. Dordrecht, Netherlands/Norwell, MA: Kluwer
28. 28. Ikegawa S, Yi S, Araki S, et al. 1990. Reevaluation of 134 patients with familial amyloidotic polyneuropathy (FAP) type I in Japan, Kumamoto focus. In Amyloid and Amyloidosis, ed. JB Navtig, Ø Førre, G Husby, et al, pp. 675-78. Dordrecht, Netherlands/Norwell, MA: Kluwer
29. 29. Holmgren G, Haettner E, Nordenson I, et al. 1988. Homozygosity for the transthyretin-met 30 gene in two Swedish sibs with familial amyloidotic polyneuropathy. Clin. Genet. 34:333-38
30. 30. K Yoshioka, H Furuya, H Sasaki, et al. 1989. Haplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val-Met mutation most common to the disease. Hum. Genet. 82:9-13
31. 31. Reilly MM, Adams D, Davis MB, et al. 1995. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (Met 30 and Tyr 77). J. Neurol. 242:664-68
32. 32. Ikeda S, Takei Y, Nakazato M, et al. 1999. Geographic distribution of familial amyloid polyneuropathy (FAP) in Japan. Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Umeå, Sweden, P38:62
33. 33. Sousa A, Andersson R, Drugge U, et al. 1993. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum. Hered. 43:288-94
34. 34. Holmgren G, Costa PM, Andersson C, et al. 1994. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J. Med. Genet. 31:351-54
35. 35. Holmgren G, Ando Y, Wikström L, et al. 1997. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP)(TTR Met 30). Amyloid: Int. J. Exp. Clin. Invest. 4:178-80
36. 36. Soyka J. 1876. Ueber amyloide degeneration. Prag. Med. Wochenschr. 9:165-71
37. 37. Beneke R, Bönning F. 1908. Ein fall von lokaler amyloidose des herzens. Beitr. Pathol. Anat. 44:362-85
38. 38. Westermark P, Sletten K, Johansson B, Cornwell GG III. 1990. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87:2843-45
39. 39. Gorevic PD, Prelli FC, Wright J, et al. 1989. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J. Clin. Invest. 83:836-43
40. 40. Jacobson DR, Gorevic PD, Buxbaum JN. 1990. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am. J. Hum. Genet. 47:127-36
41. 41. Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. 1991. Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (Ile-122). J. Lab. Clin. Med. 117:175-80
42. 42. Saraiva MJM, Sherman W, Marboe C, et al. 1990. Cardiac amyloidosis: report of a patient heterozygous for the transthyretin-isoleucine 122 variant. Scand. J. Immunol. 32:341-46
43. 43. Snyder EC, Nichols WC, Liepnicks JJ, Benson MD. 1991. Direct evidence for hereditary nature of senile cardiac (systemic) amyloidosis. Am. J. Hum. Genet. 45:A220 (Abstr.)
44. 44. Jacobson DR, Pastore R, Pool S, et al. 1996. Revised transthyretin Ile 122 allele prevalence in African-Americans. Hum. Genet. 98:236-38
45. 45. Booth DR, Gillmore JD, Persey MR, et al. 1999. TTR mutations in patients with senile cardiac amyloidosis. In Amyloidosis, ed. MA Gertz, RA Kyle, pp. 554-55. New York, London: Parthenon
46. 46. Jacobson DR, Pastore RD, Yaghoubian R, et al. 1997. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 336:466-73
47. 47. Kohno K, Palha JA, Miyakawa K, et al. 1997. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol. 150:1497-508
48. 48. Yamamura K. 1999. Development of mouse models for determination of factors involved in amyloidogenesis. Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy Other Transthyretin Relat. Disord., 4th, Umeå, Sweden, S2:37
49. 49. Teng M, Yin J, Vidal R, et al. 1998. Age and sex-dependent amyloid fibril formation in mice transgenic for wild type human transthyretin. J. Invest. Med. 46:192A (Abstr.)
50. 50. Buxbaum JN. 1997. The amyloidoses. In Rheumatology, ed. JH Klippel, PA Dieppe, pp. 27.1-10. London: Mosby-Wolfe
51. 51. Sipe JD 1994. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31:325-54
52. 52. Shiroo M, Kawahara E, Nakanishi I, Migita S. 1988. SAA2 deposition in the spleen of the mouse. In Amyloid and Amyloidosis, ed. T Isobe, S Araki, F Uchino, et al., pp. 63-68. London/New York: Plenum
53. 53. Lavie G, Zucker-Franklin D, Franklin EC. 1978. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J. Exp. Med. 148:1020-31
54. 54. Nomenclature Committee of the International Society of Amyloidosis. 1999. Revised nomenclature for serum amyloid A (SAA). Amyloid: Int. J. Exp. Clin. Invest. 6:67-70
55. 55. Liepnieks JJ, Kluve-Beckerman B, Benson MD. 1995. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim. Biophys. Acta 1270:81-86
56. 56. Booth DR, Booth SE, Gillmore JD, et al. 1998. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 5:262-65
57. 57. Faulkes DJ, Woo P. 1997. Do alleles at the serum amyloid A locus influence susceptibility to reactive amyloidosis in systemic onset juvenile chronic arthritis? Amyloid: Int. J. Exp. Clin. Invest. 4:75-79
58. 58. Yamada T, Okuda Y, Itoh Y. 1998. The frequency of serum amyloid A2 alleles in the Japanese population. Amyloid: Int. J. Exp. Clin. Invest. 5:208-11
59. 59. Samuels J, Aksentijevich I, Torosyan Y, et al. 1998. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 77:268-97
60. 60. Zemer D, Pras M, Sohar E, et al. 1986. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J. Med. 314:1001-5
61. 61. Zemer D, Revach M, Pras M, et al. 1974. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N. Engl. J. Med. 291:932-37
62. 62. The French FMF Consortium. 1997. A candidate gene for familial Mediterranean fever. Nature Genet. 17:25-30
63. 63. The International FMF Consortium. 1997. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-807
64. 64. Livneh A, Langevitz P, Shinar Y, et al. 1999. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid: Int. J. Exp. Clin. Invest. 6:1-6
65. 65. Kindy MS, deBeer FC, Markesbery WR, et al. 1995. Apolipoprotein E genotypes in AA and AL amyloidoses. Amyloid: Int. J. Exp. Clin. Invest. 2:159-62
66. 66. Evans DA, Funkenstein HH, Albert MS, et al. 1989. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262:2551-56
67. 67. Glenner GG, Wong CW. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885-90
68. 68. Koo EH, Park L, Selkoe DJ. 1993. Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc. Natl. Acad. Sci. USA 90:4748-52
69. 69. Schlossmacher MG, Ostaszewski BL, Hecker LI, et al. 1992. Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes. Neurobiol. Aging 13:421-34
70. 70. Zheng H, Jiang M, Trumbauer ME, et al. 1995. Beta-amyloid precursor protein-deficient mice show gliosis and decreased locomotor activity. Cell 81: 525-31
71. 71. Kang J, Lemaire H, Unterbeck A, et al. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-36
72. 72. Sandbrink R, Masters CL, Beyreuther K. 1996. APP gene family. Alternative splicing generates functionally related isoforms. Ann. NY Acad. Sci. 777:281-87
73. 73. De Strooper B, Annaert W, Cupers P, et al. 1999. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518-22
74. 74. Iwatsubo T, Odaka A, Suzuki N, et al. 1994. Visualization of A beta 42(43)-positive and A beta 40-positive senile plaques with end-specific A beta-monoclonal antibodies: evidence that an initially deposited A beta species is A beta 1-42(43). Neuron 13:45-53
75. 75. Citron M, Oltersdorf T, Haass C, et al. 1992. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360:672-74
76. 76. Sherrington R, Rogaev EI, Liang Y, et al. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-60
77. 77. Levy-Lahad E, Wasco W, Poorkaj P, et al. 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-77
78. 78. Suzuki N, Cheung TT, Cai XD, et al. 1994. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264:1336-40
79. 79. Armstrong RA. 1994. Differences in beta-amyloid (beta/A4) deposition in human patients with Down's syndrome and sporadic Alzheimer's disease. Neurosci. Lett. 169:133-36
80. 80. LaFerla FM, Tinkle BT, Bieberich CJ, et al. 1995. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nature Genet. 9:21-30
81. 81. Van Nostrand WE, Davis-Salinas J, Saporito-Irwin SM. 1996. Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann. NY Acad. Sci. 777:297-302
82. 82. Blacker D, Tanzi RE. 1998. The genetics of Alzheimer disease: current status and future prospects. Arch. Neurol. 55:294-96
83. 83. Bird TD, Levy-Lahad E, Poorkaj P, et al. 1996. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann. Neurol. 40:932-36
84. 84. Goate A, Chartier-Harlin M-C, Mullan M, et al. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-6
85. 85. Wisniewski T, Frangione B 1992. Molecular biology of Alzheimer's amyloid-Dutch variant. Mol. Neurobiol. 6:75-86
86. 86. Mullan M, Crawford F, Axelman K, et al. 1992. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nature Genet. 1:345-47
87. 87. Levy E, Carman MD, Fernandez-Madrid IJ, et al. 1990. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124-26
88. 88. Schellenberg GD, Bird TD, Wijsman EM, et al. 1992. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258: 668-71
89. 89. Tomita T, Maruyama K, Saido TC, et al. 1997. The presenilin-2 mutation (N1411) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc. Natl. Acad. Sci. USA 94:2025-30
90. 90. Wolfe MS, Xia W, Ostaszewski BL, et al. 1999. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513-17
91. 91. De Strooper B, Saftig P, Craessaerts K, et al. 1998. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-90
92. 92. Levitan D, Greenwald I. 1995. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377: 351-54
93. 93. Baumeister R, Leimer U, Zweckbronner I, et al. 1997. Human presenilin 1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signaling independently of proteolytic processing. Genes Funct. 1:149-59
94. 94. Nishimura M, Yu G, Levesque G, et al. 1999. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nature Med. 5:164-69
95. 95. Weidemann A, Paliga K, Durrwang U, et al. 1997. Formation of stable complexes between two Alzheimer's diseases gene products: presenilin-2 and beta-amyloid precursor protein. Nature Med. 3:328-32
96. 96. Rogaev EI, Sherrington R, Rogaeva EA, et al. 1995. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-78
97. 97. Games D, Adams D, Alessandrini R, et al. 1995. Alzheimer-type neuropathology in transgenic mice overproducing V717F beta-amyloid precursor protein. Nature 373:523-27
98. 98. Hsiao K, Chapman P, Nilsen S, et al. 1996. Correlative memory deficits, A beta elevation and amyloid plaques in transgenic mice. Science 274:99-102
99. 99. Holcomb L, Gordon MN, McGowan E, et al. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4:97-100
100. 100. Sturchler-Pierrat C, Abramowski D, Duke M, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94:13287-92
101. 101. Kowal RC, Herz J, Goldstein JL, et al. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesterol esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA 86:5810-14
102. 102. Beisiegel U, Weber W, Ihrke G, et al. 1989. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 341:162-64
103. 103. Gallo G, Wisniewski T, Choi-Miura N-H, et al. 1994. Potential role of apolipoprotein-E in fibrillogenesis. Am. J. Pathol. 145:526-30
104. 104. Dong LM, Wilson C, Wardell MR, et al. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269:22358-65
105. 105. Franceschini G. 1996. Apolipoprotein function in health and disease: insights from natural mutations. Eur. J. Clin. Invest. 26:733-46
106. 106. Kamboh MI, Sepehrnia B, Ferrell RE. 1989. Genetic studies of human apolipoproteins. VI. Common polymorphism of apolipoprotein E in blacks. Dis. Markers 7:49-55
107. 107. Schächter F, Faure-Delanef L, Guénot F, et al. 1994. Genetic associations with human longevity at the Apo E and ACE loci. Nature Genet. 6:29-32
108. 108. Van Bockxmeer FM, Mamotte CDS. 1992. Apolipoprotein E4 homozygosity in young men with coronary heart disease. Lancet 340:879-80
109. 109. Gejyo F, Suzuki S, Kimura H, et al. 1997. Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele. Amyloid: Int. J. Exp. Clin. Invest. 4:13-17
110. 110. Saunders AM, Strittmatter WJ, Schmechel D, et al. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-72
111. 111. Corder EH, Saunders AM, Risch NJ, et al. 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7:180-84
112. 112. Polvikoski T, Sulkava R, Haltia M, et al. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333:1242-47
113. 113. Blacker D, Haines JL, Rodes L, et al. 1997. Apo E-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48:139-47
114. 114. Sorbi S, Nacmias B, Forleo P, et al. 1995. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann. Neurol. 38: 124-27
115. 115. Wisniewski T, Castano EM, Golabek AA, et al. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1030-35
116. 116. Bales KR, Verina T, Dodel RC, et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nature Genet. 17:263-64
117. 117. Maestre G, Ottman R, Stern Y, et al. 1995. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann. Neurol. 37:254-59
118. 118. Mayeux R, Saunders AM, Shea S, et al. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease centers consortium in apolipoprotein E and Alzheimer's disease. N. Engl. J. Med. 338:506-11
119. 119. Narita M, Holtzman DM, Schwartz AL, Bu G. 1997. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69:1904-11
120. 120. Blacker D, Wilcox MA, Laird NM, et al. 1998. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 19:357-60
121. 121. Hughes SR, Khorkova O, Goyal S, et al. 1998. Alpha 2-macroglobin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. USA 95:3275-80
122. 122. Liao A, Nitsch RM, Greenberg SM, et al. 1998. Genetic association of an alpha 2-macroglobulin (Val1000Ile) polymorphism and Alzheimer's disease. Hum. Mol. Genet. 7:1953-56
123. 123. Castillo GM, Ngo C, Cummings J, et al. 1997. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 69:2452-65
124. 124. van Leeuwen FW, de Kleijn DP, van den Hurk HH, et al. 1998. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279:242-47
125. 125. Van Allen MW, Frohlich JA, Davis JR, et al. 1969. Inherited predisposition to generalised amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy and peptic ulcer. Neurology 19:10-25
126. 126. Vigushin DM, Gough J, Allan D, et al. 1994. Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q.J. Med. 87:149-54
127. 127. Westermark P, Mucchiano G, Marthin T, et al. 1995. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am. J. Pathol. 147:1186-92
128. 128. Sorci-Thomas M, Kearns MW, Lee JP, et al. 1993. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships. J. Biol. Chem. 268: 21403-9
129. 129. Amarzguioui M, Mucchiano G, Häggqvist B, et al. 1998. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with apolipoprotein A1 mutation. Biochem. Biophys. Res. Commun. 242:534-39
130. 130. Rader DJ, Gregg RE, Meng MS, et al. 1992. In vivo metabolism of a mutant apolipoprotein, apoA-1Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J. Lipid Res. 33:755-58
131. 131. Soutar AK, Hawkins PN, Vigushin DM, et al. 1992. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc. Natl. Acad. Sci. USA 89:7389-93
132. 132. Booth DR, Tan SY, Booth SE, et al. 1995. A new apolipoprotein A1 variant, Trp50Arg, causes hereditary amyloidosis. Q.J. Med. 88:695-702
133. 133. Booth DR, Yan SY, Booth SE, et al. 1996. Hereditary hepatic and systemic amyloidosis caused by a new deletion/ insertion mutation in the apolipoprotein AI gene. J. Clin. Invest. 97:2714-21
134. 134. Persey MR, Booth DR, Booth SE, et al. 1998. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-1. Kidney Int. 53:276-81
135. 135. Hamidi Asl K, Liepnieks JJ, Nakamura M, et al. 1999. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem. Biophys. Res. Commun. 257: 584-88
136. 136. Hamidi Asl L, Liepnicks JJ, Hamidi Asl K, et al. 1999. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am. J. Pathol. 154:221-27
137. 137. Goldfarb LG, Brown P. 1995. The transmissible spongiform encephalopathies. Annu. Rev. Med. 46:57-65
138. 138. Westermark P, Araki S, Benson MD, et al. 1999. Part 1. Nomenclature of amyloid fibril proteins. Amyloid: Int. J. Exp. Clin. Invest. 6:63-66